Compositions and methods of using CRMP-1 and its fragments for treating cancer
AssigneeAdvpharma Inc.
InventorsHarn-Jing Terng, Yi-Jen Lee, Woan-Jen Lee
Life of this patent
Estimating the term…
Abstract
The present invention discloses a method for treating cancer by using hCRMP1 and/or active fragments thereof, as well as the active fragments of hCRMP1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. A vector capable of expressing an hCRMP1, a variant of hCRMP1, a fragment of hCRMP1 or a variant of a fragment of hCRMP1 is also disclosed.
Claims18
An isolated nucleic acid sequence, being selected from the group consisting of SEQ ID NOs:
- 16, 18, 20, 22, 24, 26, 33, 34, 35, 36, 37, and 38, wherein the isolated nucleic acid sequence encodes a fragment of CRMP-1, in which the fragment is active in inhibiting the proliferation, metastasis, and/or invasion of a cancer cell.
An isolated polynucleic acid, which is a polynucleotide fragment of SEQ ID NO:
- 16 and comprises the nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 18, 20, 22, 24, 34, 35, 36, and 37, wherein the isolated polynucleic acid encodes an active fragment of CRMP-1.
An isolated nucleic acid sequence, being selected from the group consisting of SEQ ID NOs:
- 18, 20, 22, 24, 26, 34, 35, 36, 37, and 38, wherein the isolated nucleic acid sequence encodes a fragment of CRMP-1 that is active in inhibiting the proliferation, metastasis, and/or invasion of a cancer cell.
An isolated nucleic acid sequence, which encodes a fragment of CRMP-1, wherein the fragment of CRMP-1 is selected from the group consisting of SEQ ID NOs:
- 15, 17, 19, 21, 23, 25, and 39-43 and is active in inhibiting the proliferation, metastasis, and/or invasion of a cancer cell, and wherein the nucleic acid has no more than 1500 nucleotides in length.
An isolated nucleic acid sequence, which encodes a fragment of CRMP-1, wherein the fragment is selected from the group consisting of SEQ ID NOs:
- 17, 19, 21, 23, 25 and 39-43 and is active in inhibiting the proliferation, metastasis, and/or invasion of a cancer cell, wherein the isolated nucleic acid sequence is selected from the group consisting of SEQ ID NOs:
- 18, 20, 22, 24, 26, and 34-38.
A recombinant vector for expression of a fusion protein, comprising:
- (a) a first nucleotide sequence, which encodes an HIV protein transduction domain (PTD);
- and
- (b) a second nucleotide sequence, which encodes an active fragment of CRMP-1 and is fused in translation frame to the HIV PTD, wherein the active fragment of CRMP-1 is selected from the group consisting of SEQ ID NOs:
- 15, 17, 19, 21, 23, 25, and 39-43;
- and wherein the active fragment of CRMP-1 encoded thereby has no more than 500 amino acids in length, and further wherein the vector does not fully encode SEQ ID NO:1.
A recombinant vector for expression of a fusion protein, comprising:
- (a) a first nucleotide sequence, which encodes an HIV protein transduction domain (PTD);
- and
- (b) a second nucleotide sequence, which encodes an active fragment of CRMP-1 and is fused in translation frame to the HIV PTD, wherein the second nucleotide sequence is selected from the group consisting of SEQ ID NOs:
- 16, 18, 20, 22, 24, 26, and 33-38;
- wherein the active fragment of CRMP-1 encoded thereby has no more than 500 amino acids in length, and wherein the vector does not fully encode SEQ ID NO:1.
Dependencies are inferred from the claim text.